Piper Jaffray Expands Health Care Expertise With Addition of New Biotechnology Research Team
08 April 2008 - 11:00PM
Business Wire
Piper Jaffray today announced it has expanded its investment
research health care team with the addition of Andrew Fein as a
senior research analyst. He will be based in New York and provide
coverage of companies in the biotechnology sector. Fein joins Piper
Jaffray from Collins Stewart where he was previously a managing
director and senior equity analyst covering the biotechnology
sector. His prior experience includes covering biotech companies as
a senior analyst at Leerink Swann, and as a biotech analyst at
Deutsche Bank and JPMorgan. He earned a bachelor�s degree in
biology and history from Yale University and also pursued a medical
degree at the New York University School of Medicine. Fein has
received �Honorable Mention� in Institutional Investor�s annual
poll since 2002. Caroline Tao and Sarah Chu will also join Fein on
the biotechnology team in New York as research associates. Tao and
Chu both received bachelor�s degrees in brain and cognitive science
from MIT and previously worked for Collins Stewart. In addition,
Manisha Narasimhan will join the broader biotechnology team at
Piper Jaffray as a research associate. She was previously a
consultant at Campbell Alliance where she was responsible for
developing strategies for pharmaceutical and biotech clients. She
earned a bachelor�s degree from the University of Madras, a
master�s degree in molecular biology from Bowling Green State
University and a Ph.D. from the New York University School of
Medicine. �Andrew and our new research associates bring significant
industry knowledge and research excellence to Piper Jaffray,
helping us to further strengthen our research expertise in the
biotechnology sector and build our health care franchise at the
firm,� says Joel Denney, head of investment research at Piper
Jaffray. In addition to research expertise in the biotechnology
sector, Piper Jaffray provides coverage of companies in the
following health care sectors: health care services, medical
technology, medical diagnostics, specialty pharmaceuticals, and
drug discovery. The firm is also one of the most active
underwriters for growth companies in the health care sector and has
been ranked as a top equity underwriter in the sector since
2004(a). (a)Source: Dealogic & Piper Jaffray Equity Capital
Markets About Piper Jaffray Piper Jaffray Companies is a leading,
international middle-market investment bank and institutional
securities firm, serving the needs of middle-market corporations,
private equity groups, public entities, nonprofit clients and
institutional investors. Founded in 1895, Piper Jaffray provides a
comprehensive set of products and services, including equity and
debt capital markets products; public finance services; mergers and
acquisitions advisory services; high-yield and structured products;
institutional equity and fixed-income sales and trading; and equity
and high-yield research. With headquarters in Minneapolis, Piper
Jaffray has 25 offices across the United States and international
locations in London, Hong Kong, and Shanghai. Piper Jaffray &
Co. is the firm's principal operating subsidiary. (NYSE: PJC)
(http://www.piperjaffray.com) Since 1895. Member SIPC and FINRA. �
2008 Piper Jaffray & Co., 800 Nicollet Mall, Suite 800,
Minneapolis, Minnesota 55402-7020
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Piper Jaffray Companies (New York Stock Exchange): 0 recent articles
More Piper Jaffray News Articles